Zivo Bioscience (ZIVO) CFO files Form 3 showing no equity or derivatives

Rhea-AI Filing Summary

Zivo Bioscience, Inc. reported insider information for its Chief Financial Officer, William A. Sullivan, in a Form 3 initial ownership filing. The filing shows that as of the event date of 12/19/2025, he reported beneficial ownership of 0 shares of Zivo Bioscience, Inc. common stock and no derivative securities such as options or warrants. The form is filed as an individual reporting person and confirms that he currently holds no direct or indirect equity or derivative position in the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sullivan William A.

(Last) (First) (Middle)

2125 BUTTERFIELD ROAD

SUITE 100

(Street)

TROY MI 48084

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/19/2025

3. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned.	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ William A. Sullivan	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filing for ZIVO disclose about insider ownership?

The Form 3 shows that Zivo Bioscience, Inc.'s Chief Financial Officer, William A. Sullivan, reported beneficial ownership of 0 shares of the company’s securities as of 12/19/2025, with no derivative securities listed.

What is the role of the reporting person in Zivo Bioscience, Inc. (ZIVO)?

The reporting person, William A. Sullivan, is identified as an officer of Zivo Bioscience, Inc., serving in the position of Chief Financial Officer.

Does the ZIVO Chief Financial Officer hold any derivative securities?

In Table II of the Form 3, no derivative securities are reported. The filing indicates no options, warrants, or other convertible instruments beneficially owned by the Chief Financial Officer.

Is this ZIVO Form 3 filed by one or multiple reporting persons?

The document states that the Form 3 is filed by one reporting person, indicating it only covers the holdings of William A. Sullivan.

What address is associated with the reporting person in the ZIVO Form 3?

The address listed is 2125 Butterfield Road, Suite 100, which is provided in the filer information section.

When was the Zivo Bioscience, Inc. ownership event that triggered this Form 3?

The date of the event requiring the statement is given as 12/19/2025, which is the reference date for the ownership status reported.